GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļGSK
āļāļ·āđāļāļāļĢāļīāļĐāļąāļGSK plc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 22, 1972
āļāđāļāļāļąāđāļāđāļĄāļ·āđāļ1999
āļāļĩāļāļĩāđāļMs. Deborah Waterhouse
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ68629
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 22
āļāļĩāđāļāļĒāļđāđ980 Great West Road
āđāļĄāļ·āļāļBRENTFORD
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđLondon Stock Exchange
āļāļĢāļ°āđāļāļĻUnited Kingdom
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđTW8 9GS
āđāļāļĢāļĻāļąāļāļāđ442080475000
āđāļ§āđāļāđāļāļāđhttps://www.gsk.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļGSK
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 22, 1972
āļāđāļāļāļąāđāļāđāļĄāļ·āđāļ1999
Dr. Hal V. Barron, M.D.
Non-Executive Director
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
Mr. James Ford
Senior Vice President, Group General Counsel, Legal and Compliance
Senior Vice President, Group General Counsel, Legal and Compliance
Ms. Sally Jackson
Senior Vice President - Global Communications and CEO Office
Senior Vice President - Global Communications and CEO Office
Dr. Tony Wood, Ph.D.
Chief Scientific Officer
Ms. Julie Brown
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Hal V. Barron, M.D.
Non-Executive Director
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
VanEck Pharmaceutical ETF
The Opal International Dividend Income ETF
USCF Dividend Income Fund
Sound Equity Dividend Income ETF
Brandes International ETF
Altrius Global Dividend ETF
Pacer Global Cash Cows Dividend ETF
Fidelity Blue Chip Value ETF
Fidelity Women's Leadership ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
VanEck Pharmaceutical ETF
āļŠāļąāļāļŠāđāļ§āļ4.97%
The Opal International Dividend Income ETF
āļŠāļąāļāļŠāđāļ§āļ4.51%
Keating Active ETF
āļŠāļąāļāļŠāđāļ§āļ3.76%
USCF Dividend Income Fund
āļŠāļąāļāļŠāđāļ§āļ3.61%
Sound Equity Dividend Income ETF
āļŠāļąāļāļŠāđāļ§āļ3.48%
Brandes International ETF
āļŠāļąāļāļŠāđāļ§āļ3.35%
Altrius Global Dividend ETF
āļŠāļąāļāļŠāđāļ§āļ2.06%
Pacer Global Cash Cows Dividend ETF
āļŠāļąāļāļŠāđāļ§āļ2.01%
Fidelity Blue Chip Value ETF
āļŠāļąāļāļŠāđāļ§āļ1.56%
Fidelity Women's Leadership ETF
āļŠāļąāļāļŠāđāļ§āļ1.29%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
20.79B
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
GSK.NB Approximate interim Cash Dividend of gross USD 0.400652 paid on Apr 10, 2025 going ex on Feb 21, 2025
GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024
GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024
GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024
GSK.NB Interim Cash Dividend of gross USD 0.404885 paid on Apr 11, 2024 going ex on Feb 22, 2024
GSK.NB Final Cash Dividend of gross USD 0.356356 paid on Jan 11, 2024 going ex on Nov 16, 2023
GSK.NB Interim Cash Dividend of gross USD 0.343532 paid on Oct 12, 2023 going ex on Aug 17, 2023
GSK.NB Interim Cash Dividend of gross USD 0.360944 paid on Jul 13, 2023 going ex on May 18, 2023
GSK.NB Interim Cash Dividend of gross USD 0.341883 paid on Apr 13, 2023 going ex on Feb 23, 2023
GSK.NB Final Cash Dividend of gross USD 0.334785 paid on Jan 12, 2023 going ex on Nov 17, 2022
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ